Novo Nordisk A/S - Reduction of the share capital
- 36
Bagsværd, Denmark, 24 April 2019 - At Novo Nordisk's Annual General Meeting on 21 March 2019, it was decided to reduce the company's B share capital from DKK 382,512,800 to DKK 372,512,800 by cancellation of part of the company's portfolio of own B shares equal to a nominal value of DKK 10,000,000 divided into 50,000,000 B shares of DKK 0.20 each.
Today, Novo Nordisk has registered the implementation of the reduction of the share capital with the Danish Business Authority and cancelled B shares at a nominal value of DKK 10,000,000. After the reduction of the share capital, the company's share capital is nominally DKK 480,000,000, which is divided into an A share capital of nominally DKK 107,487,200 and a B share capital of nominally DKK 372,512,800.
The reduction of the share capital will not affect Novo Nordisk's share repurchase programme which will continue as previously announced.
Further information
| Media: | ||
| Anne Margrethe Hauge | +45 4442 3450 | [email protected] |
| Ken Inchausti (US) | +1 609 786 8316 | [email protected] |
| Investors: | ||
| Peter Hugreffe Ankersen | +45 3075 9085 | [email protected] |
| Valdemar Borum Svarrer | +45 3079 0301 | [email protected] |
| Ann Søndermølle Rendbæk | +45 3075 2253 | [email protected] |
| Kristoffer Due Berg (US) | +1 609 235 2989 | [email protected] |
Company announcement no. 24 / 2019
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Globenewswire
GlobeNewswire Europe, a Nasdaq company, is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
